Working… Menu

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00650923
Recruitment Status : Completed
First Posted : April 2, 2008
Last Update Posted : May 30, 2014
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase I trial is studying the side effects and best dose of aflibercept when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or recurrent glioblastoma multiforme, gliosarcoma, or other malignant glioma. Aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving aflibercept together with radiation therapy and temozolomide may kill more tumor cells.

Condition or disease Intervention/treatment Phase
Adult Anaplastic Astrocytoma Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Recurrent Adult Brain Tumor Drug: ziv-aflibercept Procedure: radiation therapy Drug: temozolomide Procedure: pharmacological study Procedure: laboratory biomarker analysis Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of Aflibercept (VEGF Trap) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Glioma
Study Start Date : July 2008
Actual Primary Completion Date : June 2013
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: Arm 1
See Detailed Description
Drug: ziv-aflibercept
Given IV
Other Names:
  • aflibercept
  • vascular endothelial growth factor trap
  • VEGF Trap
  • Zaltrap

Procedure: radiation therapy
Undergo RT
Other Names:
  • irradiation
  • radiotherapy
  • therapy, radiation

Drug: temozolomide
Given PO
Other Names:
  • SCH 52365
  • Temodal
  • Temodar
  • TMZ

Procedure: pharmacological study
Correlative studies
Other Name: pharmacological studies

Procedure: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Maximum tolerated dose of aflibercept defined as the dose at which fewer than one-third of patients experience DLT based on the CTC severity grading [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Efficacy in terms of antitumor activity based on clinical, radiographic, and biologic assessments [ Time Frame: Up to 3 months ]
    Descriptive analysis will be provided.

  2. Plasma aflibercept (VEGF Trap) concentrations and PK parameters such as Cmax, Tmax, area under the plasma concentration-time curve (AUCo-t and AUC), clearance (CL), apparent volume of distribution at steady state (Vdss), and terminal half-life (t1/2) [ Time Frame: Baseline and days 15, 16, 22, 29, 57, 85 of course 1 for patients in Arm I; baseline and days 2, 8, 15, 43, 71 of course 1 for patients in Arms 2 and 3 ]
    Will be determined using non-compartmental methods. Dose proportionality in PK parameters will be determined by performing a one-way analysis of variance (ANOVA) on dose-normalized parameters. In addition, summary tables depicting individual patient concentrations and individual and mean PK parameters will be provided.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Creatinine < = 1.5 mg/dL or creatinine clearance = > 60 mL/min
  • At least 28 days since prior major surgery or open biopsy
  • INR < = 1.5
  • Not pregnant or nursing
  • Negative pregnancy test
  • Karnofsky performance status 60-100%
  • SGOT and SGPT < 2 times upper limit of normal (ULN)
  • Bilirubin < 2 times ULN
  • Life expectancy = > 12 weeks
  • WBC = > 3,000/μL
  • ANC= > 1,500/mm³
  • Platelet count = > 100,000/mm³
  • Hemoglobin = > 10 g/dL (transfusion allowed)
  • At least 21 days since prior radiotherapy (groups 2 and 3)
  • No prior Gliadel® wafers
  • No concurrent major surgery
  • Fertile patients must use effective contraception prior to, during, and for at least 6 months after completion of study treatment
  • At least 28 days since prior significant traumatic injury No evidence of bleeding diathesis or coagulopathy
  • No serious or nonhealing wound, ulcer, or bone fracture
  • No history of other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years
  • No history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess gastrointestinal bleeding or diverticulitis within the past 6 months
  • No prior cranial radiotherapy (group 1 only)
  • No prior aflibercept
  • No prior treatment for brain tumors, except concurrent radiotherapy and temozolomide or 2 or fewer 28-day courses of adjuvant temozolomide (groups 2 and 3)
  • No prior or concurrent cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors (group 1 only)
  • No concurrent major surgery
  • No known hypersensitivity to CHO cell products or other recombinant human antibodies
  • No history of hypersensitivity to a recombinant protein whereby reaction occurs during or immediately after infusion
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to other study agents
  • No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness or social situation that would limit compliance with study requirements
  • No clinically significant cardiovascular disease within the past 6 months, including any of the following:

History of ischemic or hemorrhagic stroke

  • Myocardial infarction, coronary artery bypass graft, or unstable angina
  • New York Heart Association class III-IV congestive heart failure, serious cardiac arrhythmia requiring medication, or unstable angina pectoris
  • Clinically significant peripheral vascular disease
  • Pulmonary embolism, deep vein thrombosis, or other thromboembolic event
  • No disease that will obscure toxicity or dangerously alter drug metabolism
  • Recovered from all prior therapy
  • More than 28 days since prior and no concurrent investigational agents
  • More than 7 days since prior core biopsy
  • At least 23 days since prior temozolomide (groups 2 and 3)
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent full-dose anticoagulants (e.g., warfarin or low molecular-weight heparin)
  • Prophylactic doses allowed
  • No concurrent routine prophylactic use of filgrastim (G-CSF)
  • No other concurrent anticancer therapy (including chemotherapy, radiotherapy, hormonal treatment, or immunotherapy)
  • Concurrent enzyme-inducing antiepileptic drugs (EIAED) or non-EIAED allowed
  • Urine protein:creatinine ratio < = 1 or 24-hour urine protein < = 500 mg
  • No significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00650923

Layout table for location information
United States, California
University of California at Los Angeles (UCLA )
Los Angeles, California, United States, 90095
UCSF-Mount Zion
San Francisco, California, United States, 94115
University of California San Francisco Medical Center-Parnassus
San Francisco, California, United States, 94143
United States, Maryland
Adult Brain Tumor Consortium
Baltimore, Maryland, United States, 21231-1000
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15232
United States, Texas
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Patrick Wen National Cancer Institute (NCI)
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00650923    
Other Study ID Numbers: NCI-2009-00678
NCI-2009-00678 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NABTC07-01 ( Other Identifier: Adult Brain Tumor Consortium )
NABTC-07-01 ( Other Identifier: CTEP )
U01CA137443 ( U.S. NIH Grant/Contract )
First Posted: April 2, 2008    Key Record Dates
Last Update Posted: May 30, 2014
Last Verified: April 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Endothelial Growth Factors
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Growth Substances
Physiological Effects of Drugs